Built for hard cases
Sapian excels even in areas where traditional data-hungry AI fails. Even for targets with no 3D structure or no known modulator, Sapian finds the needle in the haystack.
HIT DISCOVERY AT SCALE FOR UNDRUGGABLE TARGETS
Sapian is a universal AI-driven small molecule discovery engine which overcomes "undruggable" barriers facing structure-based approaches thanks to novel AI models powered by hundreds of millions of datapoints.
The result: IP-clean chemistry for the most challenging therapeutic targets, selected amongst 10 billion possible candidates.
UNLOCKING STALLED DISCOVERY
Reopening closed doors
Sapian is validated in different categories of targets: ion channels, antigens, ubiquitin-line proteins, as supported by experimental data from a series of independent labs.
Exploring untapped space
Sapian routinely screens 10 billion compounds in less than a day. This represents a 10 000-fold increase compared to the average screening campaign in pharma.
Behind Sapian is a team with a mission at heart: improve human health with AI.
A personal story of one of our founding members led us to reinvent some of the core principles of how AI is used in drug discovery and become pioneers in the post-docking era.
A ROSETTA STONE FOR DRUG DISCOVERY
Find drugs faster, repeatably
Sapian can identify effective modulators for any biological target. While results vary with target complexity, no target has yet been left undrugged by Sapian. Several first-in-class molecules have already been discovered by Sapian.
Explore untapped chemical space
Sapian enables systematic exploration of vast, previously inaccessible chemical space. By revealing the potential of underexplored molecules, Sapian helps identify high-value candidates with clear rationale and strong predictive confidence.
Select drugs with less hidden risks
One of Sapian's key capabilities is to predict the pharmacodynamic and pharmacokinetic profile of drugs, across the entire eukaryotic proteome, a unique capability. In doing so, Sapian can pro-actively select the most selective drugs in silico.
Decide with predictability
Sapian was built with the obsession to bring predictability and risk mitigation to the complexity of drug discovery. Sapian augments drug discovery, enabling to identify the best drug candidates with clear safety filters, high IP potential, and high predictability.
EMBARK UPON NEXT GENERATION DRUG DISCOVERY
Partner with Kantify
Discover how to use Sapian in your own drug discovery journey.
Understand Sapian
Review how Sapian differentiates.
Review validations
Explore the breadth of validation of Sapian through experimentally validated projects.
Visit pipeline
Read our full pipeline of independently discovered assets and validation cases.
News
Updates about our projects, team and technologyQ4 Pipeline Update
Wed 17 Dec 2025
Kantify reports key scientific advances across its neurology and oncology programs this quarter.
Kantify Appoints Diana Sarkees Avoo as Junior ML Engineer
Wed 29 Oct 2025
Kantify's Machine Learning team grows with the addition of a new team member
Kantify at Bio Europe 2025
Wed 29 Oct 2025
Meet the Kantify Exec Team at Bio Europe 2025
Kantify Reaches New Milestone in AI-Driven Drug Discovery
Wed 22 Oct 2025
10 Billion Molecules Analyzed Per Day and a Major Advance in a Rare Cancer
Insights
Insights about drugs, biology, chemistry, and machine learningSapian leads to in vivo results in liposarcoma
Wed 22 Oct 2025
Kantify reports a preclinical proof-of-concept program in soft tissue sarcoma with a focus on liposarcoma
Sapian predicts targets of Paracetamol (Acetaminophen)
Wed 19 Feb 2025
Kantify publishes the AI-predicted targets of Paracetamol (Acetaminophen) and highlights possible mechanisms of action
Prostate cancer drug discovery: promising advance
Thu 12 Dec 2024
A collaboration between Kantify and Johns Hopkins School of Medicine leads to initial, promising pre-clinical results on metastatic prostate cancer